Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Clin Microbiol Infect Dis ; 40(9): 1821-1832, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-33783664

RESUMEN

Little is known about the role of lineage of strains of Clostridioides difficile (CD) on the clinical presentation of CD infection (CDI) in Latin America, especially regarding the treatment response. We conducted a multicenter, prospective study to investigate the predictive factors and treatment outcomes of CDI in hospitalized patients and to performed phenotypical and molecular characterization of CD strains. A total of 361 diarrheic patients at 5 hospitals from different regions of the country were enrolled. All stool samples were tested for glutamate dehydrogenase (GDH), toxins A and B, and toxin genes using a nucleic acid amplification test (NAAT). Specimens were cultured and susceptibility profile and whole-genome sequencing (WGS) were performed. CDI positivity was 15% (56/377). Predictive factors for CDI were prior use of meropenem (OR 4.09, 95% CI 2.097-7.095; p<0.001), mucus in stools (OR 3.29; 95% CI 1.406-7.722; p=0.006) and neutrophil left-shift with >20% of bands (OR 3.77; 95% IC 1.280-11.120; p=0.016). Overall mortality was 19%, with no deaths attributed to CDI. Oral metronidazole was used in 74% of cases, with 85% of cure and 14% of recurrence. A total of 35 CD isolates were recovered, all of them susceptible to metronidazole and vancomycin. The WGS revealed 17 different STs, six of which were novel. ST42 was the most common ST and hypervirulent strains were not found. Severe CDI were caused by ST42, ST5, ST8, ST48, ST33 and a novel ST667. The ermB gene was more frequently found in isolates of ST42 (p=0.004).


Asunto(s)
Antibacterianos/uso terapéutico , Clostridioides difficile/genética , Infecciones por Clostridium/tratamiento farmacológico , Infecciones por Clostridium/epidemiología , Diarrea/microbiología , Adulto , Anciano , Proteínas Bacterianas/genética , Brasil/epidemiología , Clostridioides difficile/clasificación , ADN Bacteriano/genética , Heces/microbiología , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Resultado del Tratamiento , Secuenciación Completa del Genoma
2.
Exp Parasitol ; 218: 107970, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32828829

RESUMEN

Visceral leishmaniasis (VL) is an anthropozoonosis endemic in Brazil. We included 20 patients with confirmed diagnosis of VL and 20 healthy individuals to evaluate the expression levels of complement receptor 1 (CR1)/CD35 and CR3/CD11b on leukocytes in the peripheral blood and determine their correlation with the clinical state of patients. CR1/CD35 expression increased on CD11b+CD35+granulocytes of patients, while CR1/CD35 and CR3/CD11b expression levels increased on CD14+CD11b+CD35+ monocytes. Among patients, those with severe clinical state had higher expression of CR3/CD11b on CD14+monocytes. The count of CD19+CD35+B lymphocytes reduced in the blood samples from patients. These observed changes may indicate the modulation in CR1/CD35 and CR3/CD11b complement receptor expressionlevels on granulocyte and monocyte populations in response to Leishmania sp.


Asunto(s)
Antígeno CD11b/metabolismo , Leishmaniasis Visceral/inmunología , Leucocitos/metabolismo , Antígeno de Macrófago-1/metabolismo , Receptores de Complemento 3b/metabolismo , Adolescente , Adulto , Anciano , Brasil/epidemiología , Enfermedades Endémicas/estadística & datos numéricos , Femenino , Citometría de Flujo , Granulocitos/inmunología , Granulocitos/patología , Humanos , Hipertrofia , Leishmaniasis Visceral/sangre , Leishmaniasis Visceral/epidemiología , Leucocitos/inmunología , Hígado/patología , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Monocitos/inmunología , Monocitos/patología , Pancitopenia , Población Rural , Bazo/patología , Población Urbana , Adulto Joven
3.
Anaerobe ; 66: 102267, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33080372
4.
Dig Dis Sci ; 62(1): 93-104, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27864656

RESUMEN

AIM: The objective was to evaluate the effects of nitric oxide (NO) and hydrogen sulfide (H2S) donors and possible interactions between these two systems in modulating gastric function. METHODS: Mice received saline, sodium nitroprusside (SNP), or sodium hydrosulfite (NaHS), and after 1 h, the animals were killed for immunofluorescence analysis of CSE or eNOS expressions, respectively. Other groups received saline, SNP, NaHS, Lawesson's reagent (H2S donor), PAG + SNP, L-NAME, L-NAME + NaHS, or L-NAME + Lawesson's reagent. Then, the gastric secretions (mucous and acid), gastric blood flow, gastric defense against ethanol, and gastric motility (gastric emptying and gastric contractility) were evaluated. RESULTS: SNP and NaHS increased the expression of CSE or eNOS, respectively. SNP or Lawesson's reagent did not alter gastric acid secretion but increased mucus production, and these effects reverted with PAG and L-NAME treatment, respectively. SNP or NaHS increased gastric blood flow and protected the gastric mucosa against ethanol injury, and these effects reverted with PAG and L-NAME treatments, respectively. SNP delayed gastric emptying when compared with saline, and PAG partially reversed this effect. NaHS accelerate gastric emptying, and L-NAME partially reversed this effect. SNP and NaHS alone induced gastric fundus and pylorus relaxation. However, pretreatment with PAG or L-NAME reversed these relaxant effects only in the pylorus but not in the gastric fundus. CONCLUSION: NO and H2S interact in gastric physiological functions, and this "cross-talk" is important in the control of mucus secretion, gastric blood flow, gastric mucosal defense, and gastric motility, but not in the control of basal gastric acid secretion.


Asunto(s)
Cistationina gamma-Liasa/efectos de los fármacos , Vaciamiento Gástrico/efectos de los fármacos , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico Sintasa de Tipo III/efectos de los fármacos , Nitroprusiato/farmacología , Estómago/efectos de los fármacos , Sulfuros/farmacología , Alquinos/farmacología , Animales , Depresores del Sistema Nervioso Central/farmacología , Cistationina gamma-Liasa/antagonistas & inhibidores , Cistationina gamma-Liasa/metabolismo , Interacciones Farmacológicas , Inhibidores Enzimáticos/farmacología , Etanol/farmacología , Técnica del Anticuerpo Fluorescente , Ácido Gástrico/metabolismo , Fundus Gástrico/efectos de los fármacos , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Glutatión/efectos de los fármacos , Glutatión/metabolismo , Glicina/análogos & derivados , Glicina/farmacología , Flujometría por Láser-Doppler , Masculino , Malondialdehído/metabolismo , Ratones , Moco/efectos de los fármacos , Moco/metabolismo , Contracción Muscular/efectos de los fármacos , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa de Tipo III/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo III/metabolismo , Píloro/efectos de los fármacos , Ratas , Ratas Wistar , Flujo Sanguíneo Regional , Estómago/irrigación sanguínea
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA